HIV Infections Clinical Trial
— PIPOfficial title:
Using Incentives to Improve Parolee Participation and Attendance in Community Tx
Verified date | May 2017 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse
Programs (ISAP), in collaboration with Walden House and the California Department of
Corrections and Rehabilitation, is conducting a five-year study that will involve a
randomized test of the use of incentives with parolees in a community-based residential
substance abuse treatment program to increase treatment admission and treatment retention,
and thereby increase the likelihood of improved outcomes. Study participants will be
recruited from clients in a prison-based treatment program who have a referral to the Walden
House community program. The Admission Phase of the study assesses the effect of an
incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses
the effect of incentives on treatment attendance and on post-treatment drug use, crime, and
psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol
will test whether an incentive will encourage participation in HIV testing and counseling.
The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in
community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in
community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in
HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the
intervention. Treatment and criminal justice data will be obtained. Data on acceptability,
satisfaction, and sustainability will be collected from focus groups with staff and clients.
Status | Completed |
Enrollment | 202 |
Est. completion date | August 2014 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - At least 18 years of age - English speaking - Within one month of parole - Able to provide informed consent to participate in the study - Received a referral to the Walden House Los Angeles Transitional Treatment Center Exclusion Criteria: - Potential subjects will be excluded from participating if they have serious cognitive problems that preclude their ability to provide informed consent or understanding of the questionnaire items, if they are a sexually violent predator or a child molester or if they have severe mental health problems. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles |
Saxena P, Hall EA, Prendergast M. A Randomized Study of Incentivizing HIV Testing for Parolees in Community Aftercare. AIDS Educ Prev. 2016 Apr;28(2):117-27. doi: 10.1521/aeap.2016.28.2.117. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Community treatment admission | Within 7 days of release to parole | ||
Primary | Community treatment retention | 6 months | ||
Primary | Participation in HIV testing and counseling | 2 months | ||
Secondary | Substance abuse | 18 months after release from prison | ||
Secondary | Arrest and reincarceration | 18 months after release from prison | ||
Secondary | psychosocial: employment, education, family relationships, psychological functioning, and HIV risk | employment, education, family relationships, psychological functioning, and HIV risk | 18 months after release from prison |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |